Company news

MaxCyte, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

January 7, 2024

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

December 31, 2023

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

December 10, 2023

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

November 15, 2023

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

November 7, 2023

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

October 3, 2023

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

September 5, 2023

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

August 8, 2023

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

July 31, 2023

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

July 12, 2023

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

July 9, 2023

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

July 5, 2023

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

May 9, 2023

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

April 11, 2023

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

March 26, 2023

MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results

March 14, 2023

MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology

March 7, 2023

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance

March 5, 2023

MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences

January 31, 2023

MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs

January 2, 2023

MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases

December 3, 2022

MaxCyte Reports Third Quarter 2022 Financial Results

November 8, 2022

MaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022

October 11, 2022

MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program

September 27, 2022

MaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor

September 20, 2022

MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

August 9, 2022

MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

July 14, 2022

MaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs

July 11, 2022

MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2022

MaxCyte Reports First Quarter Financial Results

May 8, 2022

MaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022

April 19, 2022

MaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue

April 11, 2022

MaxCyte Reports Fourth Quarter and Full Year Financial Results

March 21, 2022

MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer

March 8, 2022

MaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs

January 31, 2022

MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results

January 22, 2022

MaxCyte Reports Third Quarter Financial Results

November 9, 2021

MaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs

October 27, 2021

MaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021

October 24, 2021

MaxCyte Set to Join Russell 2000® Index

September 16, 2021

MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections

September 12, 2021

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology

August 8, 2021

Financial information in the Form S-1 registration statement and Change to Board of Directors

July 12, 2021

MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing

July 12, 2021

← Newer news releases

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 13 decks. Every deck is listed under its year.